EMA Releases Pharmacogenomics Guidance - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

EMA Releases Pharmacogenomics Guidance


The European Medicines Agency has released a draft guideline that addresses how pharmacogenomics can support pharmacovigilance activities. The guideline document also details how the results of pharmacogenomics, the study of how the genetic makeup of a person affects his or her response to certain medicines, can help optimize the use of drugs. Pharmacogenomics can help target patients who are likely to respond better to the treatments and helping to mitigate and manage their risks more efficiently.

This draft guideline is directed towards the marketing authorization applicants and holders as well as academia, healthcare professionals, and national competent authorities of the European Union. The guidance provides a framework and recommendations on how to assess pharmacovigilance issues associated with pharmacogenomics, and how to translate the results of these assessments into appropriate recommendations for the labeling of drugs.

The guideline describes the use of pharmacogenomics in risk-management plans, risk-minimization measures, signal detection and the benefit-risk evaluation of drugs with an established link between genetic features and efficacy and safety. The guideline also describes different types of genomic biomarkers that can be relevant for pharmacovigilance and provides concrete examples.

Source: European Medicines Agency

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
13%
Provide treatment for patients globally.
10%
All of the above.
41%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here